Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | MIF | P14174 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 4/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.38 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26243594 | 1.00 | SLC7A5 (0.50) | SLC7A5MIFESR1ESR2POLB | |
| SCHEMBL24534511 | 1.00 | SLC7A5 (0.50) | SLC7A5MIFESR1ESR2POLB | |
| SCHEMBL13853189 | 0.86 | CYP1A2 (0.50) | SLC7A5FOLH1CPA1 | |
| SCHEMBL32665976 | 0.86 | CYP1A2 (0.50) | SLC7A5FOLH1CPA1 | |
| SCHEMBL13853218 | 0.85 | CPA1 (0.44) | CA2ACECPA1CTBP2LDHA | |
| SCHEMBL26243831 | 0.83 | LDHA (0.61) | POLBCTBP2LDHA | |
| SCHEMBL27181638 | 0.83 | LDHA (0.61) | POLBCTBP2LDHA | |
| SCHEMBL24534564 | 0.81 | MIF (0.60) | MIFESR1ESR2 | |
| SCHEMBL24534570 | 0.81 | MIF (0.60) | MIFESR1ESR2 | |
| SCHEMBL27181532 | 0.81 | MIF (0.60) | MIFESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522592-B2 | ERAP inhibitors | UNIVERSITE DE LILLE (FR) | 2026-01-13 | — | — | US | disclosed |
| EP-4263533-B1 | ERAP INHIBITORS | UNIV LILLE (FR) | 2025-08-20 | — | — | EP | disclosed |
| US-20240101542-A1 | ERAP INHIBITORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2024-03-28 | — | — | US | disclosed |
| WO-2022129589-A9 | ERAP INHIBITORS | UNIVERSITE DE LILLE (FR) | 2023-08-24 | — | — | WO | disclosed |
| WO-2022129589-A1 | ERAP INHIBITORS | UNIVERSITE DE LILLE (FR) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101542-A1 | ERAP INHIBITORS | ERAP2, ERAP1, ERMP1 | SLC7A5 2968/4885MIF 737/4885ESR1 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.